In addition, the dabrafenib plus trametinib combination therapy is approved for the treatment of patients with BRAF V600 mutation-positive advanced nonsmall cell lung cancer [40,41,42,43] and showed substantial promise in numerous BRAF-dysregulated solid tumor types [44,45,46,47,48], including thyroid cancers [12,13,29,49]. Here, BRAF is linked to thyroid cancer.